Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
European Journal of Nuclear Medicine and Molecular Imaging|January 27, 2020
<sup>18</sup>F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patientsPanli Li, Xiuying Wang, Chongrui Xu, et al.
Theranostics|August 2, 2019
<sup>18</sup>F-FDG PET/CT Radiomic Analysis with Machine Learning for Identifying Bone Marrow Involvement in the Patients with Suspected Relapsed Acute LeukemiaHebei Li, Chongrui Xu, Bowen Xin, et al.
Thoracic Cancer|November 4, 2016
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasisQiuyi Zhang, Xuchao Zhang, Honghong Yan, et al.
Zhonghua Yi Xue Za Zhi|November 18, 2014
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma]Nana Lou, Jinji Yang, Honghong Yan, et al.
BMC Cancer|April 25, 2019
Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell levelLonghua Guo, Zhihong Chen, Chongrui Xu, et al.
Oncotarget|December 22, 2016
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinomaQiuyi Zhang, Ee Ke, Feiyu Niu, et al.
JCO Precision Oncology|September 14, 2020
Genomic Characterization of <i>ERBB2</i>-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab EmtansineSebastian Mondaca, Pedram Razavi, Chongrui Xu, et al.
Future Oncology (London, England)|March 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumorsYi-Long Wu, Ying Cheng, Huajun Chen, et al.
Chinese Medical Journal|April 27, 2026
Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs. immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world studyZijian Huang, Shiqi Mei, Jiaqi Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Pageof 3